Accordingly, the presence of PD-L1+ NK cells in blood of acute myeloid leukemia patients was recently reported, and treatment with atezolizumab, a humanized anti-PD-L1 mAb, increased the effector functions of PD-L1+ NK cells (56). The gene discussed is CD274; the disease is acute myeloid leukemia.